| Field | Specification |
|---|---|
| Target | |
| CAS no. | |
| Applications | |
| Molecular weight | |
| Molecular formula | C32H31N7O3 |
| SMILES | |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
JNK3 inhibitor-7 is a potent, orally active JNK3 inhibitor that crosses the blood-brain barrier, with IC50 values of 53 nM, 973 nM and 1039 nM against JNK3, JNK2 and JNK1, respectively. It shows significant neuroprotective effects and has potential application in Alzheimer's disease (AD) research[1]. It has the molecular formula C32H31N7O3 and a molecular weight of 561.63 g/mol.
Physical & Chemical Properties
| CAS Number | 3034676-52-0 |
|---|---|
| Molecular Formula | C32H31N7O3 |
| Molecular Weight | 561.63 g/mol |
| SMILES | CNC(OC1=CC=C2N=C(C3=CC4=C(C=CC=C4)C=C3)N(C5=NC(N[C@@H]6CN(CCC6)C(C7CC7)=O)=NC=C5)C2=C1)=O |
| Target | JNK3, JNK2, JNK1 |
| Signaling Pathway | MAPK/ERK Pathway |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Biological Activity
IC50 & Target[1]
|
JNK3 53 nM (IC50) |
JNK2 973 nM (IC50) |
JNK1 1039 nM (IC50) |
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with your institution's chemical hygiene plan.
In Vitro
When primary rat cortex neurons are treated with 10 μM amyloid-β1-42, JNK3 inhibitor-7 (20 μM; 24, 48 h) increases their cell viability[1].
Cell Viability Assay[1]
| Cell Line | primary rat cortex neuron cells |
|---|---|
| Concentration | 20 μM |
| Incubation Time | 24, 48 h |
| Result | Increased cell viability when treatment with 10 μM amyloid-β1-42. |
In Vivo
In mice, JNK3 inhibitor-7 given at 30 and 60 mg/kg (p.o.; daily for 4 weeks) has significant neuroprotective effects[1].
Pharmacokinetic Parameters of JNK3 inhibitor-7 in Sprague-Dawley rats[1]
| compound | 2h |
| admin. | PO |
| dose (mg/kg) | 3 |
| AUClast (h ng/ml) | 350.68 |
| C0 or Cmax (ng/mL) | 342.30 |
| Tmax (h) | 0.39 |
| T1/2 (h) | 0.65 |
Dosing in Sprague-Dawley rats: 3 mg/kg, p.o.[1]
| Animal Model | 7 month-old APP/PS1 AD mice[1] |
|---|---|
| Dosage | 30, 60 mg/kg |
| Administration | P.o.; daily for 4 weeks |
| Result | Decreased the escape time and distance traveled, a dose-dependent increased in the quadrant where the escape zone was located and the time spent. |
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
